Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS INC (REGN), sold 2,506 shares at $522.80 ($1.3M) on 2017-06-22, disclosed to the SEC on 2017-06-23.
Open-market sale of $1.3M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $521.70 | 100 | $52K | 3.9% |
| 2 | $522.80 | 200 | $105K | 7.8% |
| 3 | $524.08 | 101 | $53K | 4.0% |
| 4 | $531.42 | 900 | $478K | 35.9% |
| 5 | $533.49 | 905 | $483K | 36.2% |
| 6 | $537.42 | 200 |
| $107K |
| 8.1% |
| 7 | $541.70 | 100 | $54K | 4.1% |
| Total | $531.68 avg | 2,506 | $1.3M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |